Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial, SAKK 19/05.

Francesco Zappa,C. Droege,D.C. Betticher,R. von Moos,Martin Brutsche,Florent Baty,Lukas Bubendorf,Adrian F. Ochsenbein,E Oppliger-Leibundgut,Oliver Gautschi,Patrizia Froesch,Rolf A. Stahel,Dieter Rauch,Pirmin Schmid,Michael Mayer,Susanne Crowe,P. Brauchli,Karin Ribi,Miklos Pless

Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial, SAKK 19/05.

2011

Francesco Zappa
C. Droege
D.C. Betticher
R. von Moos
Martin Brutsche
Florent Baty
Lukas Bubendorf
Adrian F. Ochsenbein
E Oppliger-Leibundgut
Oliver Gautschi
Patrizia Froesch
Rolf A. Stahel
Dieter Rauch
Pirmin Schmid
Michael Mayer
Susanne Crowe
P. Brauchli
Karin Ribi
Miklos Pless

7561 Background: Standard CT is toxic and yields unsatisfactory results in advanced NSCLC. The aim of this trial was to evaluate feasibility and efficacy of BE first-line combination, followed by C...

Keywords:

non-small cell lung cancer (NSCLC)
Bevacizumab
Erlotinib
Cancer research
Chemotherapy
Pathology
Disease
Oncology
Internal medicine
Medicine
disease progression
first line therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations